Patrick Johnson appointed to Aviceda Therapeutics’ board of directors
Private clinical-stage biotech, Aviceda Therapeutics has announced that it has appointed Patrick Johnson to its board of directors.
Johnson has vast experience of business
with entrepreneurial expertise, and has seen various pharmaceutical and biotechnology companies maximise the value of their brands and realise the potential of their innovations. His experience spans various areas of corporate operations, including global M&A, business development, strategic transactions, fundraising, clinical operations, scientific research and corporate finance.
Mohamed A Genead MD CEO and president of Aviceda Therapeutics, commented: “We are thrilled to welcome Patrick to Aviceda’s board of directors as we advance our pipeline through key milestones in 2023 and beyond. Patrick will bring significant industry expertise, and his strategic counsel will be invaluable to Aviceda as we continue to advance our technology platform in late-stage clinical development for patients with geographic atrophy (GA) due to age-related macular degeneration and broader therapeutic applications.”
Johnson added: “It is a privilege to join Aviceda’s board as the organisation advances towards delivering new treatment options for people living with retinal diseases, many of whom have been significantly underserved for decades. I look forward to working alongside this dynamic team and advancing a diverse pipeline through development and into commercialisation.”